Edwards Lifesciences CorpEW
Price$85.19Intrinsic value$74.9312% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $6.5B+19.7% YoYTTM through 30 Jun 2026
Net Income $1B-75.9% YoYTTM through 30 Jun 2026
Free Cash Flow $1.4BTTM through 30 Jun 2026

Margins

Current
Gross Margin77.8%
EBITDA Margin24.8%
Operating Margin22.3%
Net Margin15.4%

Returns

9.5%ROE
7.2%ROA
12.1%ROIC

Balance Sheet Health

Debt / Equity0.06x
Current Ratio4.52x
Net Debt-$2.3Bnet cash position
Cash & Equivalents$2.9B

Quality Metrics

Altman Z-Score12.55
Piotroski F-Score7 / 9
FCF Margin22.0%
Rule of 4025.8
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $6.1B
Diluted EPS$1.72TTM
'19'20'21'22'23'24'25
FY2025: $1.83

Dividend

No dividend

Capital Allocation

R&D Spend$1.1B
Capex Intensity4.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.